主要文件

查看所有文档

47674

FFmoc-N-三苯甲基-L-谷氨酰胺

Name: FFmoc-N-三苯甲基-L-谷氨酰胺
Brand: ALDRICH

≥98.0% (HPLC), for peptide synthesis

别名:

N_α-Fmoc-N_δ-三苯甲基-L-谷氨酰胺

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₃₉H₃₄N₂O₅

化学文摘社编号:

132327-80-1

分子量:

610.70

UNSPSC Code:

12352209

eCl@ss:

32160406

PubChem Substance ID:

57651077

NACRES:

NA.26

Beilstein/REAXYS Number:

4343953

MDL number:

MFCD00077056

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

FFmoc-N-三苯甲基-L-谷氨酰胺, ≥98.0% (HPLC)

Quality Level

100

assay

≥98.0% (HPLC)

form

powder

optical activity

[α]/D -14.0±1.5°, c = 1% in DMF

reaction suitability

reaction type: Fmoc solid-phase peptide synthesis

application(s)

peptide synthesis

functional group

Fmoc

storage temp.

2-8°C

SMILES string

OC(=O)[C@H](CCC(=O)NC(c1ccccc1)(c2ccccc2)c3ccccc3)NC(=O)OCC4c5ccccc5-c6ccccc46

InChI

1S/C39H34N2O5/c42-36(41-39(27-14-4-1-5-15-27,28-16-6-2-7-17-28)29-18-8-3-9-19-29)25-24-35(37(43)44)40-38(45)46-26-34-32-22-12-10-20-30(32)31-21-11-13-23-33(31)34/h1-23,34-35H,24-26H2,(H,40,45)(H,41,42)(H,43,44)/t35-/m0/s1

InChI key

WDGICUODAOGOMO-DHUJRADRSA-N

说明

General description

Fmoc-Gln(Trt)-OH 也称 Nα-Fmoc-Nδ-三苯甲基-L-谷氨酰胺，它是 Fmoc 保护的氨基酸衍生物，可用作合成肽的试剂。由于谷氨酰胺受到三苯甲基保护，因此可以防止在反应中出现不需要的取代产物。

Application

Fmoc-Gln(Trt)-OH可用作Fmoc 固相肽合成的原料，用于合成fellutamide B 和 fellutamide B的N-辛酰基类似物。

Still not finding the right product?

Explore all of our products under FFmoc-N-三苯甲基-L-谷氨酰胺

存储类别

11 - Combustible Solids

wgk

WGK 1

ppe

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Inhibition of Kallikrein-Related Peptidases 7 and 5 by Grafting Serpin Reactive-Center Loop Sequences onto Sunflower Trypsin Inhibitor-1 (SFTI-1).

Cathleen Jendrny et al.

Chembiochem : a European journal of chemical biology, 17(8), 719-726 (2015-11-18)

Serpin proteins irreversibly inhibit serine proteases, but only a small part of the serpin reactive-center loop (RCL) is responsible for the initial protein-protein interaction (PPI). To develop peptidic protease inhibitors, kallikrein-related peptidases 7 (KLK7) and 5 (KLK5) were chosen. Firstly

Inhibition of Tau Protein Aggregation by Rhodanine-based Compounds Solubilized Via Specific Formulation Additives to Improve Bioavailability and Cell Viability.

Marcus Pickhardt et al.

Current Alzheimer research, 14(7), 742-752 (2017-02-06)

Anti-aggregation drugs play an important role in therapeutic approaches for Alzheimer's disease. We have previously developed a number of compounds that are able to inhibit the pathological aggregation of Tau protein. One common obstacle to application is the limited penetration

Intradermal drug delivery by nanogel-peptide conjugates; specific and efficient transport of temoporfin.

Fatemeh Zabihi et al.

Journal of controlled release : official journal of the Controlled Release Society, 242, 35-41 (2016-07-30)

Nanogels offer many unique features rendering them as very attractive candidates for drug delivery. However, for their applications the loading capacity and specific encapsulation, in particular for hydrophobic drugs, in a complex media are two critical factors. In this work

查看所有相关文献

全球贸易项目编号

货号	GTIN
47674-25G-F	04061832372730
47674-5G-F	04061832372747
47674-100G-F	04061832372723
47674-1KG-F	04061826222805